Axe Compute Inc. Common Stock

AGPU

Market cap $20.2M

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU) (the “Company” or “Axe Compute”) today announced that it has changed its name to Axe Compute Inc., with its common stock to begin trading on Nasdaq under the ticker symbol AGPU on December 12, 2025. Axe Compute will continue to operate its AI-driven drug discovery business and plans to expand its business into high-performance enterprise AI infrastructure, addressing rising global demand for predictable, scalable compute capacity across enterprise AI workloads.

Predictive Oncology Inc. ( POAI ) Q3 2025 Earnings Call November 17, 2025 9:00 AM EST Company Participants Raymond Vennare - CEO & Chairman Joshua Blacher - Interim Chief Financial Officer Thomas McLaughlin Kyle Okamoto Presentation Operator Before we begin, let me quickly remind you that during the course of this presentation, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement.

PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million as of the signing of the private placements.

Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors

Investment creates the world's first Strategic Compute Reserve  Strategy complements Predictive Oncology's AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) (Nasdaq: POAI) today announced the closing of two previously announced private investment in public equity transactions (“PIPEs”) totaling approximately $343.5 million to support the Company's adoption of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem. The Company raised an aggregate of approximately $343.5 million in the PIPEs from the purchase and sale of (i) an aggregate of approximately 4.4 million shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) for a purchase price of $11.6265 per share (the “Offering Price”) of common stock (or per pre-funded warrant in lieu thereof) for aggregate cash gross proceeds of approximately $50.8 million (the “Cash PIPE”), and (ii) pre-funded warrants to purchase up to approximately 14.9 million shares of common stock for a purchase price of $11.6165 per pre-funded warrant in exchange for approximately $292.7 million in notional value representing approximately $173.3 million in discounted value of in-kind contributions of locked and unlocked ATH (the “Crypto PIPE”).

Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements

Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025 Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025

Collaboration builds upon positive results utilizing Predictive Oncology's AI platform to identify new indications for existing drugs Collaboration builds upon positive results utilizing Predictive Oncology's AI platform to identify new indications for existing drugs

NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.0 million.